英国首次使用Trumenba疫苗控制幼儿园B群侵袭性脑膜炎球菌病疫情
经咽拭子采样和MATS检测发现爆发株不被4CMenB覆盖,疫情管理团队权衡利弊后为38名儿童和全体工作人员接种两剂MenB-fHbp疫苗,未发生严重不良事件。
要点
- 咽拭子采样有助于识别爆发株并评估疫苗覆盖。
- MenB-fHbp疫苗在已接种4CMenB的儿童中安全使用。
- 爆发控制需权衡超说明书使用疫苗的获益与风险。
核心结论
- 在已接种4CMenB的儿童中,使用MenB-fHbp疫苗控制B群侵袭性脑膜炎球菌病爆发是安全的。
主要发现
- 咽拭子采样检出两株MenB分离株与病例A匹配。
- 抗生素敏感性测试和MATS评估显示爆发株不被4CMenB疫苗覆盖。
- 为38名儿童和全体工作人员接种两剂MenB-fHbp疫苗,间隔4周,未发生严重不良事件。
关键数值与推荐
- 所有39名儿童和9名工作人员接受环丙沙星化学预防,并提前进行咽拭子采样。
- 38名儿童和全体工作人员接种两剂MenB-fHbp疫苗,间隔4周;一户家庭拒绝接种。
临床怎么用
- 在4CMenB接种人群中爆发B群侵袭性脑膜炎球菌病时,可考虑使用MenB-fHbp疫苗进行爆发控制。
- 咽拭子采样可用于识别爆发株和评估疫苗覆盖。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In November 2023, the UK Health Security Agency was notified of PCR-confirmed group B (MenB) invasive meningococcal disease (IMD) in a 3-year-old child (Case A), followed by probable IMD in a 2-year-old (Case B, culture and PCR tests negative) attending the same nursery. An incident management team (IMT) was convened. Both children were fully vaccinated with the MenB vaccine 4CMenB (Bexsero, GSK Biologicals). All 39 children attending the nursery and nine staff received ciprofloxacin chemoprophylaxis preceded by pharyngeal swabbing. Pharyngeal swabbing yielded two MenB isolates matching Case A. Antibiotic sensitivity testing and assessment of 4CMenB vaccine coverage using the meningococcal antigen typing system (MATS) revealed the strain was not covered by the 4CMenB vaccine. Although the alternative MenB vaccine, MenB-fHbp (Trumenba, Pfizer), is only licensed from 10 years and has never been given to children previously immunised with 4CMenB, the IMT considered the benefits of outbreak control outweighed potential risks. Two doses were given 4 weeks apart to 38 children (one family declined) and all staff; there were no serious adverse events. Our findings highlight the utility of swabbing to identify outbreak strains and provide first evidence for safe use of the MenB-fHbp vaccine in children previously vaccinated with 4CMenB.
引用
- Foster K, Heymer EJ, Campbell H, et al. First use of Trumenba (MenB-fHbp) vaccine to control a nursery outbreak of serogroup B invasive meningococcal disease involving children previously immunised with Bexsero (4CMenB), England, November 2023. Euro Surveill. 2026. PMID: 41572900. doi:10.2807/1560-7917.ES.2026.31.3.2500431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。